← brief for 2026-11-02 · Slowing decline

Dapagliflozin attenuates progression from prefrailty to frailty in patients with hypertension and chronic kidney disease

Article C Peer reviewed Observational

Key takeaways

Older adults with kidney disease and high blood pressure who took a diabetes drug called dapagliflozin had less physical decline over one year. The study followed 135 people. It shows a link, not proof of cause.

Who did this work

Pasquale Mone (University of Molise) · Davide Viggiano (University of Campania "Luigi Vanvitelli") · Antonella Pansini (Ministero della Salute) · Maria Virginia Soldovieri (University of Molise) · Giada Sabatelli (University of Molise) · Valeria Visco (University of Salerno) · Gaetano Macina (Ministero della Salute) · Eugenio Boccalone (Ministero della Salute) · Michele Ciccarelli (University of Salerno) · Giuseppe Nicola Martinelli (Istituto Neurologico Mediterraneo) · Marco Di Mauro (Ministero della Salute) · Carmine Vecchione (University of Salerno)

Source

Article · OpenAlex, CKD works · 2026-11-01
https://doi.org/10.1172/jci205416